Clinical analysis of 16 cases with primary ovarian lymphoma and review of literatures

GUO Cheng-cheng,HUANG Yan,ZHAI Lin-zhu,YE Sheng,WANG Shu-sen,HUANG Hui-qiang,SUN Xiao-fei,XU Rui-hua,XIA Zhong-jun,GUAN Zhong-zhen,LIN Tong-yu

DOI: https://doi.org/10.3969/j.issn.1009-0460.2007.07.004

2007-01-01

Chinese Clinical Oncology

Abstract:Objective:The purpose of this study is to investigate the clinical and pathological features, and the optimal treatment approach for primary ovarian non-Hodgkin's lymphoma (POL) patients. Methods:From 1986 to 2006, 16 patients who were diagnosed with POL and received treatment in our hospital were included. Results:Of the 16 patients, the age ranged from 6-56 years old with a median age of 29.5 years old. Most of the pathology diagnosis was diffused large B-cell lymphoma subtype. According to the Ann Arbor staging system, 81.3% of the patients were stage Ⅰ-Ⅱ; However, 62.5% of the patients were stage Ⅲ-Ⅳ according to FIGO staging system for ovarian carcinoma. The serum CA125 level was increased significantly at the initial diagnosis, but decreased to the normal level after induction chemotherapy. The combination treatment based on operation was a prognosis factor for POL patients. The efficacy of CHOP regimen varies according to different pathology subtypes. For all the 16 patients, the complete remission (CR) rate of was 68.8%. With a median follow-up time of 39.7 months, the relapsed rate and death rate was 54.5% and 37.5%, respectively. The 5 year overall survival and disease free survival was 40% and 62.5%, respectively. Conclusion:The serum CA125 level was an indication of tumor burden, providing the evidence of efficacy chemotherapy and good prognosis. FIGO classification was found to be a prediction of the prognosis. The optimal treatment was radical surgery operation followed by combination chemotherapy.